Guest Contributor


Organizations:
BDC Venture Capital, Delphi Ventures, Genesys Capital Partners, HIG Ventures, NeurAxon Inc, NeuroVentures Fund, OrbiMed Advisors LLC, and Ventures West Capital Ltd

NeurAxon raises US$32 million for pain research

Guest Contributor
September 19, 2007

NeurAxon Inc has secured US$32 million in series B financing for further development of its pain therapeutics targeting neuronal nitric oxide synthase (nNOS) for the treatment of neuropathic pain and migraines. Created in 2004, the Toronto-based firm is opening its US headquarters in Waltham MA this fall. Leading the latest financing is Delphi Ventures and OrbiMed Advisors LLC with participation by BDC Venture Capital, Genesys Capital Partners, HIG Ventures, NeuroVentures Fund, Ventures West Capital Ltd and NeurAxon CEO Lawrence Bloch.…


Other News

UK science office moves to new department

Research & tech parks form national association

Thunder Bay home to new medical imaging centre

NRC, NSERC and BDC team up for nanotech






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.